RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Rajesh Singh to Humans

Back to Details
This is a "connection" page, showing publications Rajesh Singh has written about Humans.
Rajesh Singh
Connection Strength
0.830
Humans
  1. McFadden M, Singh SK, Kinnel B, Varambally S, Singh R. The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer. J Ovarian Res. 2023 Nov 21; 16(1):220.
    View in: PubMed
    Score: 0.046
  2. Singh SK, Singh R. Nanotherapy: targeting the tumour microenvironment. Nat Rev Cancer. 2022 05; 22(5):258.
    View in: PubMed
    Score: 0.042
  3. Singh SK, Singh R. Cytokines and Chemokines in Cancer Cachexia and Its Long-Term Impact on COVID-19. Cells. 2022 02 08; 11(3).
    View in: PubMed
    Score: 0.041
  4. Singh SK, Singh R. Surface Plasmon Resonance, a Novel Technique for Sensing Cancer Biomarker: Folate Receptor and Nanoparticles Interface. Methods Mol Biol. 2022; 2413:211-228.
    View in: PubMed
    Score: 0.041
  5. Singh SK, Singh S, Singh R. Targeting novel coronavirus SARS-CoV-2 spike protein with phytoconstituents of Momordica charantia. J Ovarian Res. 2021 Sep 27; 14(1):126.
    View in: PubMed
    Score: 0.040
  6. Singh SK, Gordetsky JB, Bae S, Acosta EP, Lillard JW, Singh R. Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer. Cells. 2020 08 27; 9(9).
    View in: PubMed
    Score: 0.037
  7. Noel B, Singh SK, Lillard JW, Singh R. Role of natural compounds in preventing and treating breast cancer. Front Biosci (Schol Ed). 2020 03 01; 12(1):137-160.
    View in: PubMed
    Score: 0.036
  8. Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020 01; 1873(1):188314.
    View in: PubMed
    Score: 0.035
  9. Singh SK, Mishra MK, Singh R. Hypoxia-inducible factor-1a induces CX3CR1 expression and promotes the epithelial to mesenchymal transition (EMT) in ovarian cancer cells. J Ovarian Res. 2019 May 10; 12(1):42.
    View in: PubMed
    Score: 0.034
  10. Singh SK, Lillard JW, Singh R. Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer. Cancer Lett. 2018 07 28; 427:49-62.
    View in: PubMed
    Score: 0.031
  11. Singh SK, Mishra MK, Eltoum IA, Bae S, Lillard JW, Singh R. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci Rep. 2018 01 22; 8(1):1323.
    View in: PubMed
    Score: 0.031
  12. Singh R, Mishra MK, Aggarwal H. Inflammation, Immunity, and Cancer. Mediators Inflamm. 2017; 2017:6027305.
    View in: PubMed
    Score: 0.030
  13. Singh SK, Singh S, Lillard JW, Singh R. Drug delivery approaches for breast cancer. Int J Nanomedicine. 2017; 12:6205-6218.
    View in: PubMed
    Score: 0.030
  14. Singh SK, Banerjee S, Acosta EP, Lillard JW, Singh R. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway. Oncotarget. 2017 Mar 07; 8(10):17216-17228.
    View in: PubMed
    Score: 0.029
  15. Banerjee S, Singh SK, Chowdhury I, Lillard JW, Singh R. Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer. Front Biosci (Elite Ed). 2017 03 01; 9(2):235-245.
    View in: PubMed
    Score: 0.029
  16. Singh SK, Lillard JW, Singh R. Molecular basis for prostate cancer racial disparities. Front Biosci (Landmark Ed). 2017 01 01; 22(3):428-450.
    View in: PubMed
    Score: 0.029
  17. Singh R, Kapur N, Mir H, Singh N, Lillard JW, Singh S. CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and av?3 integrin clustering. Oncotarget. 2016 Feb 09; 7(6):7343-53.
    View in: PubMed
    Score: 0.027
  18. Singh R, Gupta P, Kloecker GH, Singh S, Lillard JW. Expression and clinical significance of CXCR5/CXCL13 in human non-small cell lung carcinoma. Int J Oncol. 2014 Dec; 45(6):2232-40.
    View in: PubMed
    Score: 0.025
  19. Singh R, Gupta P, Sharma PK, Ades EW, Hollingshead SK, Singh S, Lillard JW. Prediction and characterization of helper T-cell epitopes from pneumococcal surface adhesin A. Immunology. 2014 Apr; 141(4):514-30.
    View in: PubMed
    Score: 0.024
  20. Singh R, Lillard JW, Singh S. Chemokines: key players in cancer progression and metastasis. Front Biosci (Schol Ed). 2011 06 01; 3(4):1569-82.
    View in: PubMed
    Score: 0.020
  21. Singh R, Stockard CR, Grizzle WE, Lillard JW, Singh S. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer. Int J Oncol. 2011 Aug; 39(2):373-81.
    View in: PubMed
    Score: 0.019
  22. Singh R, Singh S, Sharma PK, Singh UP, Briles DE, Hollingshead SK, Lillard JW. Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A. PLoS One. 2010 Feb 25; 5(2):e9432.
    View in: PubMed
    Score: 0.018
  23. Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009 Jun; 86(3):215-23.
    View in: PubMed
    Score: 0.017
  24. Darling HS, Viswanath S, Singh R, Ranjan S, Pathi N, Rathore A, Pathak A, Sud R. A clinico-epidemiological, pathological, and molecular study of lung cancer in Northwestern India. J Cancer Res Ther. 2020 Jul-Sep; 16(4):771-779.
    View in: PubMed
    Score: 0.009
  25. VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN, Lillard JW, Kittles RA, Kidd LC. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate. 2010 Mar 01; 70(4):341-52.
    View in: PubMed
    Score: 0.009
  26. Garg SK, Campbell JP, Anugwom C, Wadhwa V, Singh R, Gupta N, Sanaka MR. Incidence and Predictors of Readmissions in Acute Pancreatitis: A Nationwide Analysis. Pancreas. 2018 01; 47(1):46-54.
    View in: PubMed
    Score: 0.008
  27. Mir H, Kapur N, Singh R, Sonpavde G, Lillard JW, Singh S. Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors. Cell Cycle. 2016; 15(6):819-26.
    View in: PubMed
    Score: 0.007
  28. Mir H, Singh R, Kloecker GH, Lillard JW, Singh S. CXCR6 expression in non-small cell lung carcinoma supports metastatic process via modulating metalloproteinases. Oncotarget. 2015 Apr 30; 6(12):9985-98.
    View in: PubMed
    Score: 0.006
  29. Gupta P, Sharma PK, Mir H, Singh R, Singh N, Kloecker GH, Lillard JW, Singh S. CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis. Oncotarget. 2014 Oct 30; 5(20):10170-9.
    View in: PubMed
    Score: 0.006
  30. El-Haibi CP, Sharma P, Singh R, Gupta P, Taub DD, Singh S, Lillard JW. Differential G protein subunit expression by prostate cancer cells and their interaction with CXCR5. Mol Cancer. 2013 Jun 18; 12:64.
    View in: PubMed
    Score: 0.006
  31. Akama T, Virtucio C, Dong C, Kimura R, Zhang YK, Nieman JA, Sharma R, Lu X, Sales M, Singh R, Wu A, Fan XQ, Liu L, Plattner JJ, Jarnagin K, Freund YR. Structure-activity relationships of 6-(aminomethylphenoxy)-benzoxaborole derivatives as anti-inflammatory agent. Bioorg Med Chem Lett. 2013 Mar 15; 23(6):1680-3.
    View in: PubMed
    Score: 0.005
  32. Hernandez V, Cr?pin T, Palencia A, Cusack S, Akama T, Baker SJ, Bu W, Feng L, Freund YR, Liu L, Meewan M, Mohan M, Mao W, Rock FL, Sexton H, Sheoran A, Zhang Y, Zhang YK, Zhou Y, Nieman JA, Anugula MR, Keramane el M, Savariraj K, Reddy DS, Sharma R, Subedi R, Singh R, O'Leary A, Simon NL, De Marsh PL, Mushtaq S, Warner M, Livermore DM, Alley MR, Plattner JJ. Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria. Antimicrob Agents Chemother. 2013 Mar; 57(3):1394-403.
    View in: PubMed
    Score: 0.005
  33. Freund YR, Akama T, Alley MR, Antunes J, Dong C, Jarnagin K, Kimura R, Nieman JA, Maples KR, Plattner JJ, Rock F, Sharma R, Singh R, Sanders V, Zhou Y. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett. 2012 Sep 21; 586(19):3410-4.
    View in: PubMed
    Score: 0.005
  34. Borgegard T, Jur?us A, Olsson F, Rosqvist S, Sabirsh A, Rotticci D, Paulsen K, Klintenberg R, Yan H, Waldman M, Stromberg K, Nord J, Johansson J, Regner A, Parpal S, Malinowsky D, Radesater AC, Li T, Singh R, Eriksson H, Lundkvist J. First and second generation ?-secretase modulators (GSMs) modulate amyloid-? (A?) peptide production through different mechanisms. J Biol Chem. 2012 Apr 06; 287(15):11810-9.
    View in: PubMed
    Score: 0.005
  35. Moktar A, Singh R, Vadhanam MV, Ravoori S, Lillard JW, Gairola CG, Gupta RC. Cigarette smoke condensate-induced oxidative DNA damage and its removal in human cervical cancer cells. Int J Oncol. 2011 Oct; 39(4):941-7.
    View in: PubMed
    Score: 0.005
  36. El-Haibi CP, Singh R, Sharma PK, Singh S, Lillard JW. CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation. Cell Prolif. 2011 Aug; 44(4):311-9.
    View in: PubMed
    Score: 0.005
  37. Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JW, Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol. 2011 May 03; 9:46.
    View in: PubMed
    Score: 0.005
  38. Johnson-Holiday C, Singh R, Johnson E, Singh S, Stockard CR, Grizzle WE, Lillard JW. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol. 2011 May; 38(5):1279-85.
    View in: PubMed
    Score: 0.005
  39. Johnson EL, Singh R, Singh S, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol. 2010 Jul 22; 8:62.
    View in: PubMed
    Score: 0.005
  40. El Haibi CP, Sharma PK, Singh R, Johnson PR, Suttles J, Singh S, Lillard JW. PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Mol Cancer. 2010 Apr 22; 9:85.
    View in: PubMed
    Score: 0.005
  41. Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LW, Didier PJ, Grizzle WE, Lillard JW. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer. 2009 Nov 15; 125(10):2288-95.
    View in: PubMed
    Score: 0.004
  42. Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LW, Cooper CR, Novakovic KR, Grizzle WE, Lillard JW. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett. 2009 Sep 28; 283(1):29-35.
    View in: PubMed
    Score: 0.004
  43. Singh UP, Singh R, Singh S, Karls RK, Quinn FD, Taub DD, Lillard JW. CXCL10+ T cells and NK cells assist in the recruitment and activation of CXCR3+ and CXCL11+ leukocytes during Mycobacteria-enhanced colitis. BMC Immunol. 2008 Jun 04; 9:25.
    View in: PubMed
    Score: 0.004
  44. Singh UP, Venkataraman C, Singh R, Lillard JW. CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr Metab Immune Disord Drug Targets. 2007 Jun; 7(2):111-23.
    View in: PubMed
    Score: 0.004
  45. Singh UP, Singh S, Singh R, Karls RK, Quinn FD, Potter ME, Lillard JW. Influence of Mycobacterium avium subsp. paratuberculosis on colitis development and specific immune responses during disease. Infect Immun. 2007 Aug; 75(8):3722-8.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support